In last trading session, Neurogene Inc (NASDAQ:NGNE) saw 0.32 million shares changing hands with its beta currently measuring 1.26. Company’s recent per share price level of $24.50 trading at -$1.3 or -5.04% at ring of the bell on the day assigns it a market valuation of $363.94M. That closing price of NGNE’s stock is at a discount of -204.04% from its 52-week high price of $74.49 and is indicating a premium of 49.02% from its 52-week low price of $12.49. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.97 million shares which gives us an average trading volume of 310.06K if we extend that period to 3-months.
For Neurogene Inc (NGNE), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.14. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Neurogene Inc (NASDAQ:NGNE) trade information
Upright in the red during last session for losing -5.04%, in the last five days NGNE remained trading in the green while hitting it’s week-highest on Wednesday, 11/27/24 when the stock touched $24.50 price level, adding 11.49% to its value on the day. Neurogene Inc’s shares saw a change of 26.42% in year-to-date performance and have moved 57.15% in past 5-day. Neurogene Inc (NASDAQ:NGNE) showed a performance of -43.99% in past 30-days. Number of shares sold short was 0.91 million shares which calculate 7.15 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 47.5 to the stock, which implies a rise of 48.42% to its current value. Analysts have been projecting 45 as a low price target for the stock while placing it at a high target of 54. It follows that stock’s current price would drop -83.67% in reaching the projected high whereas dropping to the targeted low would mean a loss of -83.67% for stock’s current value.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -16.09% during past 5 years. In 2024, company’s earnings growth rate is likely to be around -245.34% while estimates for its earnings growth in next 5 years are of 25.10%.
On the other hand, BlackRock Health Sciences Term Trust and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jun 30, 2024 , the former fund manager was holding 372.05 shares of worth $9.46 million or 2.50% of the total outstanding shares. The later fund manager was in possession of 335.98 shares on Jun 30, 2024 , making its stake of worth around $8.54 million in the company or a holder of 2.26% of company’s stock.
